Navigation Links
Refractory Hematological Malignances Treatment Opportunities Discussed in MP Advisors Report Published at MarketPublishers.com
Date:9/12/2013

London, UK (PRWEB) September 12, 2013

Recently, cancer treatment has witnessed considerable breakthroughs in terms of the development of innovative drug products. The success in clinical research in this therapeutic area and growth in investments are attributed to positive clinical data and regulatory approvals, expanding partnerships and mergers and acquisitions (M&A) activity.

Some companies that have already scored a success in the development of novel technology platforms and drugs to treat relapsed and refractory multiple myeloma (RRMM), are expected to follow a similar scenario to unfold in the treatment of recurrent/refractory MDS (RR-MDS, High-Risk MDS) and AML (relapsed/ refractory AML, R/R AML).

Insightful research report “Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics” worked out by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies – Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics
Published: August, 2013
Pages: 37
Price:    US$ 2,500.00
http://marketpublishers.com/report/company_reports/treating-refractory-hematological-malignancies-v-myelodysplastic-syndromes-mds-n-acute-myeloid-leukemia-aml-emerging-therapeutics.html

The report offers an insightful overview of the approved therapies for MDS and AML, discusses the unmet needs as well as limitations of the current standard of care (SOC) for relapsed and refractory patients. The study examines commercial opportunities in purchasing the therapy area, evaluates the competitive pressure in the sphere; makes up a comprehensive list of drugs (both early-stage and late-stage) in the clinic, and also uncovers data on their mechanism of action and companies developing them; besides profiling the leading companies. The report presents a review of the recent mergers and acquisitions in the area; covers products available for in-licensing; discusses the major trends and issues related to the therapeutic area.

Report Scope:

  •     Insightful overview of the disease and a detailed discussion of the unmet needs.
  •     Vital information on the drugs in pipeline including mechanism of action (MoA) and clinical stage of development.
  •     Review of the key milestones.
  •     Data on the launch timeline and commercial opportunity of late-stage pipeline (RR MDS and RR AML).
  •     Extensive overview of the mergers and acquisitions and licensing deals over the past five years.
  •     Evaluation of the in-licensing and/or mergers and acquisitions opportunity.
  •     Description of the competitive scenario and detailed profiles of companies, including their clinical drug data, milestones and valuation.

More insightful research reports by MP Advisors can be found at http://marketpublishers.com/members/mpadvisors/info.html.

About Us:

MarketPublishers.com is a multilingual hypermarket offering a rich collection of comprehensive studies on various markets, sectors, industries, companies, etc. We perform professional services aimed to equip our clients with high-quality research products and support critical decision-making.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11117498.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
3. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
4. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
5. Clinical insight improves treatment with new lung cancer drug
6. Rapid Asthma Treatment in ER May Prevent Admission
7. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Mobile Stroke Units Might Trim Time to Treatment
11. Breast Cancer Treatment Side Effects May Last for Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could ... in the United States may be taken over by technology in the next five ... steamrolls over colleagues is drawing to a close. Success will belong to those who ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans and ... that we all are aware of our options and are empowered with strength ... the launch of its newest edition of "Vision and Hearing" in USA Today, ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The ... national conference convening academic faculty engaged in or interested in palliative care education and ... will be held in North County San Diego on Sept. 28 and 29, ...
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top ... mannequin art competition. Selected from 15 submissions from around the nation, the top five ... annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Physician General Dr. Rachel Levine ... Jennifer Smith commended South Central EMS today ... using naloxone, a life-saving overdose reversal drug. The recognition ... specialist and overdose survivor who was saved due to ... "A significant part of fighting the opioid epidemic is ...
(Date:2/24/2017)... , Feb. 23, 2017 The U.S. ... the PhenoTest BC Kit, performed on the Pheno ... organisms that cause bloodstream infections and provide information ... respond to (antibiotic sensitivity). The test also reduces ... this important information, which can guide antibiotic treatment ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
Breaking Medicine Technology: